InspireMD Announces Talks Featuring CGuard and CGuard Prime at VEITHsymposium 2026
Key Highlights
- ➤C-GUARDIANS II primary endpoint results scheduled for presentation November 20
- ➤C-GUARDIANS III trial status update scheduled alongside C-GUARDIANS II results
- ➤Three-year follow-up data covers 621 asymptomatic patients from the CGUARDIANS trial
- ➤InspireMD’s CGuard and CGuard Prime platforms featured in multiple VEITHsymposium 2026 talks
Expert Statements
Piotr Musialek, Professor of Cardiovascular Medicine at Jagiellonian University Medical College and St. John Paul II Hospital
“Progress And Updated Clinical Trials with the CGuard And CGuard Prime MicroMesh Covered Stents (From InspireMD) Including 3-Year Follow-Up Data On 621 Asymptomatic Patients: Are These MCSTs Making a Positive Difference Without Downsides: Should They Become First Line Therapy for All CAS And TCAR Procedures”
Patrick J. Geraghty, Professor of Surgery and Radiology at Washington University School of Medicine in St. Louis, Missouri
“Primary Endpoint Results of the InspireMD C-GUARDIANS II MICROMESH STENT TCAR Trial, And Update On C-GUARDIANS III Trial Status: Will This System Optimize Carotid Stenting”
MIAMI, Nov. 16, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that multiple talks featuring CGuard® and the CGuard Prime carotid stent platform are scheduled to take place at VEITHsymposium 2026, being held November 17–21, 2026, in New York City.
The talks will highlight primary endpoint results from the C-GUARDIANS II trial and the status of the ongoing C-GUARDIANS III trial of the SwicthGuard neuroprotection system (“NPS”) and three-year follow-up data involving 621 asymptomatic patients from the CGUARDIANS trial, among other sessions on the benefits of the CGuard Stent.
Get started
Create a free account to read the full story.
